It was a good first quarter for Amgen.
Product sales during the first quarter of 2015, were 12% higher, total revenue grew 11% and net income rose 34% when all compared to the same period last year, according to Medical Marketing & Media.
What is driving this? Experts say higher prices and increased demand are part of the reason.
Sales of Enbrel, a drug used to treat rheumatoid arthritis also rose 13%, whiles sales of Xgeva increase by 22%, in the first quarter of this year compared to last year during the same period, according to the article.
This comes as the company introduced its cardiovascular strategy, which includes a sales push of Corlanor, a heart failure medication recently approved by the FDA.